Strategic leader and influencer on Global Pathogen Safety (GPS) Leadership team responsible to jointly define, drive, and deliver overall GPS strategy.Lead Scientific Advocate for Global Pathogen Safety at CSL in charge of growing pathogen safety awareness internally and driving external advocacy strategy.

www.cavabio.com | I provide strategic insights and tactical counsel in marketing, life cycle management, product development and launch, medical affairs, KOL engagement, and portfolio/asset valuation. * Recognized as a trusted advisor for biopharma, CROs, biotech start-ups, and equity investors.* Attained online certification in generative AI, leveraging these cutting-edge tools to enhance and expedite marketing strategy and tactics.

Consultant within the MedSurgPI (www.medsurgpi.com) network, a specialized consultancy offering product development and medical affairs consulting focusing on the expansion of MedSurgPI's strategic services.

Spearheaded strategic initiatives for new product development, product launches, and sales training within the leading pre-IPO life sciences metabolomics service provider. Conducted comprehensive market research, including customer interviews, to identify unmet needs and establish the target product profile. Collaborated with R&D and regulatory teams to drive all product development projects. Developed commercial forecast models for all products in development, defined pricing through market research, and spearheaded risk assessment and mitigation for commercial risks. Worked closely with sales to develop and lead sales training for all new products.* Orchestrated the successful launch of five innovative metabolomics commercial panels addressing pivotal research domains such as diabetes, inflammation, lipidomics, and cannabinoids.* Implemented a comprehensive voice of the customer market research process, established target product profiles, outlined product requirements, and developed accurate forecasts.

Senior Director at plasma protein therapeutics manufacturer Talecris Biotherapeutics (acquired by Grifols in 2011). Directed global marketing efforts spanning diverse brands and therapeutic areas. Delivered comprehensive annual plans encompassing global strategic plans, long-range plans, budgets, branding guidelines, global franchise workshops, congress management, market research, and KOL engagement.* Steered launch and commercial initiatives for fostamatinib (Tavlesse®), Grifols' inaugural oral therapy for chronic ITP; assisted in the due diligence process and subsequent commercialization efforts following the in-licensing from Rigel Pharmaceuticals for European and other markets; served as global launch leader and commercial lead for the joint steering committee.* Directed global marketing for Immunoglobulins – Gamunex-C® (IVIG) and newly launched Xembify® (20% SCIG), achieving annual sales over $2.0B; formulated life cycle management plans, introducing new indications like myasthenia gravis.* Orchestrated pulmonology life cycle management for Alpha-1 Antitrypsin – Prolastin-C®, launching liquid formulation and initiating aerosol clinical program for cystic fibrosis.* Guided global launch and commercial strategy for Dual Release Ciprofloxacin – Linhaliq®, a groundbreaking solution for non-cystic fibrosis bronchiectasis.* Acted as launch lead for AlphaKit QuickScreen, a companion diagnostic point-of-care screen for alpha1-antitrypsin deficiency.* Spearheaded commercial strategy for Infectious Diseases expansion, covering rabies, HBV, RSV, influenza, Zika, CDif, Gram-negative infections, and other high-acuity infectious diseases.* Steered due diligence efforts as a commercial lead, conducting market assessments, financial analyses, and business cases for new products and indications like NMOSD, PPS, and recombinant rabies hyperimmune.

During this tenure, I led a high-performing team of Scientific Directors responsible for providing full-service scientific expertise, medical writing, and client support.

* Marketing Director, Virology. Led US marketing organization for HIV protease inhibitors Kaletra and Norvir. Managed team of 15 with full scope of responsibilities including professional promotion, consumer promotion, medical marketing, channel marketing, and managed care. * Director, Clinical Science, Virology. Led US Medical Affairs team of 25 MSLs to educate clinicians, drive thought-leader relationships, and manage investigator-initiated studies. Executed Long Range Planning and Clinical Portfolio programs including financial modeling, forecasting, and NPV analyses. Directed over 100 investigator-initiated studies and external collaborations.* Product Manager, Medical Marketing, Kaletra. Medical advisory program development and management, conference competitive intelligence, and opinion leader development. * Senior Manager, Global New Product Planning. Market research, financial modeling, and forecasting for anti-viral, anti-infective, and pain therapeutic areas. * Manager, Business Development, Abbott Renal. Developed life-cycle management strategy with Zemplar commercial team. Completed due diligence and negotiations for in-licensing of novel injectable iron oligosaccharide. * Manager, Corporate Planning and Development. Developed strategies for Abbott entry into the cardiovascular device marketplace.

Developed strategic business solutions for Fortune 500 companies in pharmaceuticals, biotech, energy, telecommunications, and life sciences sectors.

Department of Molecular Genetics and Cell Biology National Science Foundation Post-doctoral Research Fellow